Molecular imaging in clinical trials
- PMID: 19768637
- DOI: 10.1007/s11523-009-0117-x
Molecular imaging in clinical trials
Abstract
Imaging of biological processes using specific molecular probes allows exploration of the mechanism of action and efficacy for new therapies. This molecular imaging has made use of modalities including single photon emission computed tomography (SPECT), positron emission tomography (PET), magnetic resonance imaging (MRI), and optical techniques. Molecular imaging can be used to explore many of the hallmarks of cancer biology, including angiogenesis, proliferation, tissue invasion, evasion of apoptosis, and self-sufficiency in growth signals. Since many of these aspects of cancer biology are in turn the targets of novel therapies in development, molecular imaging techniques have great potential to inform trials of these new agents. The high cost of clinical drug development mandates the optimisation of early phase trial design to maximise the collection of evidence for efficacy and proof of mechanism, endpoints which have, in a number of examples, already been provided by molecular imaging. The variety provided by novel chemistry, and the availability of isotopes with varying physical properties, particularly suits PET imaging as a functional modality for application in clinical trials.
Similar articles
-
Oncologic imaging end-points for the assessment of therapy response.Recent Pat Anticancer Drug Discov. 2009 Jan;4(1):36-53. doi: 10.2174/157489209787002434. Recent Pat Anticancer Drug Discov. 2009. PMID: 19149687 Review.
-
More advantages in detecting bone and soft tissue metastases from prostate cancer using 18F-PSMA PET/CT.Hell J Nucl Med. 2019 Jan-Apr;22(1):6-9. doi: 10.1967/s002449910952. Epub 2019 Mar 7. Hell J Nucl Med. 2019. PMID: 30843003
-
Imaging Tumor Metastases with Molecular Probes.Curr Pharm Des. 2015;21(42):6260-4. doi: 10.2174/1381612821666151027153943. Curr Pharm Des. 2015. PMID: 26503140 Review.
-
Beyond RECIST: molecular and functional imaging techniques for evaluation of response to targeted therapy.Cancer Treat Rev. 2009 Jun;35(4):309-21. doi: 10.1016/j.ctrv.2008.12.001. Epub 2009 Jan 10. Cancer Treat Rev. 2009. PMID: 19136215 Review.
-
From molecular imaging in preclinical/clinical oncology to theranostic applications in targeted tumor therapy.Eur Rev Med Pharmacol Sci. 2012 Dec;16(14):1925-33. Eur Rev Med Pharmacol Sci. 2012. PMID: 23242718 Review.
Cited by
-
Molecular imaging: current status and emerging strategies.Clin Radiol. 2010 Jul;65(7):500-16. doi: 10.1016/j.crad.2010.03.011. Clin Radiol. 2010. PMID: 20541650 Free PMC article. Review.
-
Advances in Applying Computer-Aided Drug Design for Neurodegenerative Diseases.Int J Mol Sci. 2021 Apr 28;22(9):4688. doi: 10.3390/ijms22094688. Int J Mol Sci. 2021. PMID: 33925236 Free PMC article. Review.
-
Molecular imaging of tumor invasion and metastases: the role of MRI.NMR Biomed. 2011 Jul;24(6):561-8. doi: 10.1002/nbm.1590. Epub 2010 Dec 12. NMR Biomed. 2011. PMID: 21793070 Free PMC article. Review.
-
Introduction to the analysis of PET data in oncology.J Pharmacokinet Pharmacodyn. 2013 Aug;40(4):419-36. doi: 10.1007/s10928-013-9307-3. Epub 2013 Feb 27. J Pharmacokinet Pharmacodyn. 2013. PMID: 23443280 Review.
-
The changing landscape of phase I trials in oncology.Nat Rev Clin Oncol. 2016 Feb;13(2):106-17. doi: 10.1038/nrclinonc.2015.194. Epub 2015 Nov 10. Nat Rev Clin Oncol. 2016. PMID: 26552953 Review.
References
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
